US-based clinical intelligence company BioIntelliSense has received the US Food and Drug Administration (FDA) approval for its BioButton Multi-Patient wearable device and BioDashboard system to enhance hospital virtual care programmes.
BioButton is a rechargeable and reusable inpatient solution, which is said to expand the company’s continuous patient monitoring solutions portfolio.
It enables automating vital sign collection across medical-surgical units, speciality care areas, and emergency departments and delivers hospital-level care at home.
The BioDashboard clinical intelligence system offers a data-driven exception management feature that enables scalable, automated trending notifications personalised for each patient.
It allows a single clinician to monitor hundreds of patients wearing BioButton devices simultaneously in a configurable dashboard view and take proactive clinical decisions.
The continuous vital sign monitoring with its wearable device and intelligence system will allow for earlier intervention and improved patient outcomes, said the company.
BioIntelliSense founder and CEO James Mault said: “We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements each day and for every general care patient throughout their inpatient stay and now the BioButton Multi-Patient wearable is conveniently rechargeable with its own dedicated in-facility charging station.
“The introduction of the rechargeable and reusable BioButton Multi-Patient wearable, combined with the BioDashboard clinical intelligence solution, provides health systems nationwide unprecedented economies of scale in making continuous care more affordable and accessible for every patient that is admitted to the hospital.”
The new wearable device and monitoring system are part of the BioIntelliSense inpatient monitoring solution, which also includes BioHub Wi-Fi gateways and BioCloud data analytics.
The monitoring solution improves patient safety and clinical workflow by reducing the burden of repetitive manual tasks associated with spot-checking vital sign measurement and documentation.
Also, it offers a scalable continuous care model that saves staff time, resulting in better prioritisation of care and re-allocation of resources to patients who need care.
BioIntelliSense said that BioDashboard’s exception management approach to continuous patient monitoring further enhanced workforce efficiency.
Also, its low notification rates and high clinician engagement through actionable clinical insights increased response time, reduced alert fatigue, and improved overall patient care.
The BioButton and BioDashboard Systems work as a complex cloud-based platform that is interoperable with third-party and EMR systems and data exchange, said BioIntelliSense.
Last month, digital healthcare company iRhythm Technologies signed a licensing agreement with BioIntelliSense to enhance its ambulatory cardiac monitoring (ACM) capabilities.
